Natera reported accelerated Signatera minimal residual disease (MRD) growth and previewed product and regulatory milestones at JPM. The company said Q4 revenue was its fastest quarter for Signatera and that an upgraded Signatera using phased and structural variants—drawing on Foresight Diagnostics technology—will be available clinically in late spring or early summer 2026. CEO Steve Chapman and CFO Mike Brophy indicated expectations for higher average selling prices (ASPs) as Medicare reimbursement expands and additional indications are added. Natera also described plans for a multimodal MRD model that integrates ctDNA, pathology and clinical data. For clinical labs and pharma partners, the updates point to growing market traction for tumor‑informed MRD assays and continued investment in assay sensitivity and data integration.